Companies: 10,795·Total market cap: $144.5T
Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares

DMAANASDAQFinancial Services● Active
$10.62
+$0.01(+0.09%)
Market Cap$358076059
P/E Ratio—
52W High$10.62
52W Low$10.15
Net IncomeFinancialsRevenue

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

DMAA · net income · updated Jun 8, 2026

Core profitability metrics

Net income was $5.9M for FY2025 (fiscal year ending 2025-12-31), up 1240317.7% year-over-year. Net profit margin was —. Based on available data, Drugs Made In America Acquisition Corp. Ordinary Shares has been profitable since at least 2025.

FY2025 Net Income$5.9M▲ +1240317.7% YoY
Trailing 12M (TTM)$6.7Mtrailing 4 quarters sum
Net Profit Margin——
YoY Change+1240317.7%—
5-Year CAGRN/AN/A — contains loss years
FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0
Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net IncomeNet LossNet Margin %★ First Profit: 2025

▸ FMP /income-statement · Annual · DMAA net income history · DMAA profit margin

Annual net income data

Fiscal YearNet IncomeYoY ChangeNet Margin
FY2025★ First Profit$5.9M▲ +1240317.7%—
FY2024Loss−$479——

Net income vs peers (Financial Services)

#CompanyNet IncomeYoY
#1
Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. Ordinary SharesYOU
DMAA
$5.9M+1240317.7%
#2
Berkshire Hathaway Inc.
Berkshire Hathaway Inc.
BRK-A
$66.97B-24.8%#3
Berkshire Hathaway Inc.
Berkshire Hathaway Inc.
BRK-B
$66.97B-24.8%#4
JPMorgan Chase & Co.
JPMorgan Chase & Co.
JPM
$57.05B-2.4%#5
Visa Inc.
Visa Inc.
V
$20.06B+1.6%#6
Mastercard Incorporated
Mastercard Incorporated
MA
$14.97B+16.3%
Financial Services · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) reported net income of $5.9M for FY2025 (fiscal year ending 2025-12-31), up 1240317.7% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

Based on available data, Drugs Made In America Acquisition Corp. Ordinary Shares has been profitable since at least 2025. Net income reached a peak of $5.9M in FY2025. Data available for 2 fiscal years.

Drugs Made In America Acquisition Corp. Ordinary Shares's net profit margin was — for FY2025, based on the latest annual results.

Investors sometimes search for "Drugs Made In America Acquisition Corp. Ordinary Shares net worth" — the company's market capitalization is a separate figure from DMAA net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.
RevenueFinancial statementsEarningsForecastPrice historyMarket capFree cash flow

Frequently asked questions

DMAA net income · 5 questions

Drugs Made In America Acquisition Corp. Ordinary Shares is profitable. The company reported net income of $5.9M for FY2025, a net profit margin of —. Net income was up 1240317.7% year-over-year. Based on available data, Drugs Made In America Acquisition Corp. Ordinary Shares has been profitable since at least 2025.

is DMAA profitabledoes DMAA make a profitDMAA profitabilityDMAA profitable company

▸ Source: FMP /income-statement · GAAP · Drugs Made In America Acquisition Corp. Ordinary Shares · Drugs Made In America Acquisition Corp. Ordinary Shares SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026